RMD

ResMed
D

RMD

Arincen97/100B

ResMed operating income 1993–2027

ResMed's operating income in Q1 FY2027, the three months to 30 September 2026, was 452.98M USD, up 1.4% on the same quarter a year before. ResMed's operating income over the last twelve months was 1.90B USD, up 8.9% on the twelve months before. In fiscal year 2026 it was 1.91B USD, up 13.2% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Operating income

Operating income · +16.1% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 20261.90B+8.86%33.13%3.51B61.18%2.24B
FY202630 Jun 20261.91B+13.24%33.76%3.45B61.06%2.15B
FY202530 Jun 20251.69B+27.69%32.75%3.05B59.36%1.91B
FY202430 Jun 20241.32B+16.61%28.17%2.66B56.67%1.53B
FY202330 Jun 20231.13B+13.15%26.80%2.36B55.78%1.36B
FY202230 Jun 20221.00B+10.69%27.96%2.02B56.57%1.18B
FY202130 Jun 2021903.68M+11.61%28.27%1.84B57.53%1.10B
FY202030 Jun 2020809.66M+39.77%27.38%1.72B58.09%990.43M
FY201930 Jun 2019579.26M+6.91%22.22%1.54B58.95%705.80M
FY201830 Jun 2018541.83M+27.25%23.15%1.36B58.21%680.22M
FY201730 Jun 2017425.80M-0.74%20.60%1.20B58.15%568.89M
FY201630 Jun 2016428.95M+4.82%23.33%1.07B58.00%522.72M
FY201530 Jun 2015409.24M+1.02%24.38%1.01B60.24%482.29M
FY201430 Jun 2014405.09M+14.17%26.05%989.79M63.65%484.87M
FY201330 Jun 2013354.82M+20.52%23.43%940.66M62.11%469.79M
FY201230 Jun 2012294.41M+10.30%21.51%820.74M59.97%422.59M
FY201130 Jun 2011266.92M+11.04%21.47%741.33M59.63%374.32M
FY201030 Jun 2010240.38M+26.31%22.01%655.48M60.01%324.82M
FY200930 Jun 2009190.31M+33.11%20.67%553.80M60.15%255.65M
FY200830 Jun 2008142.97M+58.57%17.11%493.75M59.10%204.83M
FY200730 Jun 200790.16M-31.33%12.59%384.49M53.68%90.16M
FY200630 Jun 2006131.30M+34.87%21.63%376.90M62.09%174.04M
FY200530 Jun 200597.35M+14.05%22.88%274.86M64.60%136.90M
FY200430 Jun 200485.36M+26.95%25.16%216.74M63.87%85.36M
FY200330 Jun 200367.24M—24.58%173.09M63.27%79.82M
FY200230 Jun 2002-51.16M-296.45%-25.07%133.25M65.29%-40.84M
FY200130 Jun 200126.04M-21.41%16.78%104.78M67.53%52.16M
FY200030 Jun 200033.14M+30.98%28.66%84.87M73.41%39.39M
FY199930 Jun 199925.30M+46.24%28.56%63.80M72.01%29.90M
FY199830 Jun 199817.30M+108.43%26.02%47.10M70.83%21.00M
FY199730 Jun 19978.30M+124.32%16.87%31.50M64.02%10.90M
FY199630 Jun 19963.70M+32.14%10.69%18.90M54.62%4.90M
FY199530 Jun 19952.80M+115.38%11.91%12.80M54.47%3.40M
FY199430 Jun 19941.30M+85.71%9.35%8.00M57.55%1.60M
FY199330 Jun 1993700.00K—9.09%4.80M62.34%900.00K

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about ResMed's operating income

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.